REDWOOD CITY, Calif.,
Sept. 22, 2016 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of moderate-to-severe acute
pain, today announced that Howie
Rosen, chief executive officer, will be presenting at the
Ladenburg Thalmann 2016 Healthcare Conference. Details of the event
are as follows:
Ladenburg Thalmann 2016 Healthcare Conference
Date:
Tuesday, September 27th
Location: Sofitel, New York
Presentation Time: 3:00 pm ET
(12:00 pm PT)
The presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. The Company's
late-stage pipeline includes ARX-04 (sufentanil sublingual tablet,
30 mcg), designed for the treatment of moderate-to-severe acute
pain in medically supervised settings; and Zalviso®
(sufentanil sublingual tablet system), designed for the management
of moderate-to-severe acute pain in adult patients in the hospital
setting. Zalviso delivers 15 mcg sufentanil sublingually through a
non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. Zalviso is approved in the EU
as well as Norway, Iceland, and Liechtenstein and is investigational and in
late-stage development in the US. Grunenthal Group holds the rights
for Zalviso in Europe and
Australia, while AcelRx retains
all other world-wide rights.
Forward-Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to the process and timing of anticipated future
development of AcelRx's product candidates, ARX-04 (sufentanil
sublingual tablet, 30 mcg) and Zalviso® (sufentanil sublingual
tablet system), including the ARX-04 clinical trial results;
anticipated submission of the New Drug Application, or NDA, for
ARX-04 to the U.S. Food and Drug Administration, or FDA; AcelRx's
pathway forward towards gaining approval of Zalviso in the U.S.;
anticipated resubmission of the Zalviso NDA to the FDA; and the
therapeutic and commercial potential of AcelRx's product
candidates, including potential market opportunities for ARX-04 and
Zalviso. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and timing of events could differ materially from those
anticipated in such forward-looking statements, and as a result of
these risks and uncertainties, which include, without limitation,
risks related to AcelRx Pharmaceuticals' ARX-04 development
program, including anticipated submission of the ARX-04 NDA and the
fact that the FDA may dispute or interpret differently clinical
results obtained from the Phase 3 studies of ARX-04; AcelRx's
ability to successfully execute the pathway towards a resubmission
of the Zalviso NDA to the FDA; any delays or inability to obtain
and maintain regulatory approval of its product candidates
including ARX-04 in the United
States and Europe, and
Zalviso in the United States; the
uncertain clinical development process, including adverse events;
the risk that planned clinical trials may not have an effective
clinical design, enroll a sufficient number of patients, or be
completed on schedule, if at all; the success, cost and timing of
all development activities and clinical trials; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx's U.S.
Securities and Exchange Commission filings and reports, including
its Quarterly Report on Form 10-Q filed with the SEC on
July 29, 2016. AcelRx undertakes no
duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2016-healthcare-conference-300332217.html
SOURCE AcelRx Pharmaceuticals, Inc.